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ABSTRACT
Combined Annotation-Dependent Depletion (CADD)
is a widely used measure of variant deleteriousness
that can effectively prioritize causal variants in ge-
netic analyses, particularly highly penetrant contrib-
utors to severe Mendelian disorders. CADD is an
integrative annotation built from more than 60 ge-
nomic features, and can score human single nu-
cleotide variants and short insertion and deletions
anywhere in the reference assembly. CADD uses a
machine learning model trained on a binary distinc-
tion between simulated de novo variants and variants
that have arisen and become fixed in human popu-
lations since the split between humans and chim-
panzees; the former are free of selective pressure
and may thus include both neutral and deleterious
alleles, while the latter are overwhelmingly neutral
(or, at most, weakly deleterious) by virtue of having
survived millions of years of purifying selection. Here
we review the latest updates to CADD, including the
most recent version, 1.4, which supports the human
genome build GRCh38. We also present updates to
our website that include simplified variant lookup,
extended documentation, an Application Program In-
terface and improved mechanisms for integrating
CADD scores into other tools or applications. CADD
scores, software and documentation are available at
https://cadd.gs.washington.edu.
INTRODUCTION
Human genome sequencing is now routine, and facilitates
the ascertainment of millions of genetic variants within in-
dividuals, and hundreds of millions of variants across pop-
ulations (1). However, the interpretation of genetic vari-
ants remains an enormous challenge, and it is clear that
the further development of methods to prioritize variants
that substantially impact human phenotypes is essential to
maximize the utility of sequencing data. Genetic strategies
to identify such variants include genome-wide association,
linkage and family or trio studies. However, the resolution
of purely genetic strategies is limited by statistical power
and other factors (2). Complementary methods to priori-
tize variants based on functional or evolutionary properties
such as sequence conservation, genic effects and regulatory
element annotations can serve to improve power and ulti-
mately the success of disease studies, for both Mendelian
phenotypes (3) as well as common traits and diseases (4).
We previously described ‘Combined Annotation-
Dependent Depletion’ or CADD, a score that ranks genetic
variants, including single nucleotide variants (SNVs) and
short inserts and deletions (InDels), throughout the human
genome reference assembly (5). CADD scores are based
on diverse genomic features derived from surrounding
sequence context, gene model annotations, evolutionary
constraint, epigenetic measurements and functional pre-
dictions. For any given variant, all of these annotations are
integrated into a single CADD score via a machine learning
model. For improved interpretability, these are transformed
into a PHRED-like (i.e. log10-derived, (6)) rank score based
on the genome-wide distribution of scores for all ∼9 billion
potential SNVs, the set of all three non-reference alleles at
each position of the reference assembly.
In contrast to many other approaches, CADD is inten-
tionally not trained on the relatively limited number of ge-
nomic variants for which pathogenic or benign status is
‘known’. Rather, CADD relies on less biased, much larger
training sets. It assumes that variants that have arisen and
fixed across humanity since the last human-ape ancestor are
mostly benign or neutral since they have persisted despite
millions of years of purifying selection; for simplicity, we
will refer to these variants as proxy-neutral. Such variants
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are contrasted with a second set of simulated de novo vari-
ants that are free of selective pressure; while many such vari-
ants will also be neutral, an unknown but considerable frac-
tion would likely be deleterious, phenotypically influential
mutations if observed in an individual; for simplicity, wewill
refer to these variants as proxy-deleterious. The contrast be-
tween the proxy-neutral and proxy-deleterious variant sets,
i.e. the relative paucity of deleterious, phenotypically influ-
ential mutations in the proxy-neutral set and the resulting
differences in their annotation features, is the core charac-
teristic of CADD and motivates its name (‘CADD’).
The key advantages of theCADD framework include sys-
tematic and objective labeling of variants for the training
set, an ability to accommodate nearly any feature that can
be tied to reference assembly coordinates, and the capacity
to score both coding and non-coding variants. Each itera-
tion of the CADDmodel is trained onmore than 30 million
variants and hundreds of features derived from available an-
notations. The size of the training set allows integration of
many annotations without substantial risk of overfitting.
A limitation of CADD is that the training set label for
any given variant (i.e. proxy-neutral or proxy-deleterious)
provides an imperfect approximation of whether the vari-
ant is benign versus pathogenic. In particular, an unknown
proportion of the proxy-deleterious variants are certainly
neutral. Consequently, we do not evaluate CADD’s perfor-
mance (or select its tuning parameters) using a hold-out of
the training set. Rather, we rely on curated datasets related
to disease or functional effects across both coding and regu-
latory regions. Examples include the task of discriminating
ClinVar pathogenic (7) versus common human genetic vari-
ants (8); correlation with experimentally measured func-
tional effects in regulatory elements (9–12); and gene-wide
frequencies of somatic mutations in cancer genes (13). In
the most recent CADD version, the largest curated datasets
were split into two subsets, of which one was used to select
tuning parameters for the CADDmodel, and the other was
used to evaluate performance. To summarize, CADD does
not rely on manual/subjective variant curation in model
training, although manually curated variant sets are used
to select tuning parameters and to evaluate the overall per-
formance of CADD.
CADD FRAMEWORK
An overview of the CADD method is shown in Figure 1.
It consists of a model-fitting phase, followed by a variant-
scoring phase. Most CADD users will make use of the
model that we have already fit, and hence will interact only
with the variant-scoring phase.
In training a CADD model, we first define two variant
sets: a proxy-neutral set and a proxy-deleterious set. The
proxy-neutral variants have an allele frequency of 95–100%
in humans but are absent in the inferred genome sequence
of the human-ape ancestor (i.e. human-derived and fixed
or nearly fixed; identified from Ensembl EPO (14) whole
genome alignments; 15 million SNVs and 1.8 million In-
Dels). The sequence composition of the proxy-neutral vari-
ants is used to simulate a matching set of de novo variants,
i.e. the proxy-deleterious set.
Using more than 60 different, diverse annotations to de-
rive hundreds of numerical model features, a classification
model is trained to separate these two variant sets. Annota-
tions are obtained using Ensembl Variant Effect Predictor
(VEP (15)), conservation and selection scores (e.g. PhyloP
(16), PhastCons (17), GERP++ (18)), different tracks from
the UCSC genome browser (19) as well as flat files of epige-
netic information from the ENCODE and NIH RoadMap
projects. Annotations span a wide range of data types and
are frequently only available for subsets of variants. Exam-
ples of annotations include transcript information like dis-
tance to exon-intron boundaries, DNase hypersensitivity,
transcription factor binding, expression levels in commonly
studied cell lines and amino acid substitution scores for pro-
tein coding sequences like Grantham (20), SIFT (21) and
PolyPhen2 (22). Lists of annotations used in CADD v1.4
are available as Supplementary Tables S1 and S2. For In-
Dels, variant effects are used as predicted from VEP. For
all other annotations, the extreme values are selected from
the two neighboring positions for insertions and across the
bases of the removed range for deletions. After model train-
ing, the fitted model is applied to all ∼9 billion potential
SNVs of the human reference genome in order to calculate
raw CADD scores. A PHRED conversion table is derived
from the relative ranking of model scores across all poten-
tial SNVs (−10 log10 rank/total number of potential sub-
stitutions). Details on the different usage of these scores is
available in the section ‘Raw versus scaled scores’.
In order to score variants (defined by chromosome, po-
sition, reference and alternative allele), users provide vari-
ant sets as files in Variant Call Format (VCF), optionally
gzip-compressed or look up individual SNVs or SNV co-
ordinate ranges from the pre-scored genome files (see also
section on ‘Web access and score availability’). Variant sets
can be scored by uploading data to our web server, https:
//cadd.gs.washington.edu/ or else by using a local CADD
installation. In order to upload data to our web server, users
must confirm that they are authorized to upload the data,
that their upload does not contain any identifiable infor-
mation, and that they understand that our server does not
require user registration and that therefore data is accessi-
ble by decrypting URLs. Users, who are unable to confirm
this, have the option to score variants offline, using a lo-
cal CADD installation. Given a variant to be scored from
a variant set, the CADD score is either retrieved from an
already pre-computed file (e.g. a file of CADD scores for all
∼9 billion potential SNVs) or else obtained by annotating
the variant and applying the previously-fitted model. The
PHRED-scaled score is looked up in a conversion table and
both scores are returned to the user. In addition, the user
may request that the output files contain the variant anno-
tations used to create the CADD score.
RAW VERSUS SCALED SCORES
Two scores are returned to users for each variant. ‘Raw’
scores are the immediate output from the machine learn-
ing model. They summarize the extent to which the vari-
ant is likely to have derived from the proxy-neutral (negative
values) or proxy-deleterious (positive values) class. Because
they have no absolute meaning, they cannot be directly
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Figure 1. The CADD framework. (A) Training a CADD model requires the identification of variants that are fixed or nearly fixed in human populations,
but are absent in the inferred genome sequence of the human-ape ancestor (proxy-neutral variants). The sequence composition of this variant set is used
to draw a matching set of proxy-deleterious variants. Using more than 60 diverse annotations, a machine learning model is trained to classify variants as
proxy-neutral versus proxy-deleterious. All potential SNVs of the human reference genome are annotated using the same features, and rawCADD scores are
calculated. A PHRED conversion table is derived from the relative ranking of these model scores. (B) Users provide variant sets in VCF, and CADD uses
the chromosome, position, reference allele and alternative allele columns from these files. Scores are either retrieved from pre-scored files, or else variants
are fully annotated and the CADD score is calculated. The PHRED-scaled score is then looked up in the conversion table, and both scores returned to the
user. Users may request output files containing variant annotations.
compared across models with distinct annotation combi-
nations, training sets or tuning parameter choices. However,
raw scores do have relative meaning, in the sense that higher
values indicate that a variant is more likely to have derived
from the proxy-deleterious than the proxy-neutral variant
set, and is therefore more likely to have deleterious effects.
‘PHRED-scaled’ scores are normalized to all potential ∼9
billion SNVs, and thereby provide an externally compara-
ble unit for analysis. For example, a scaled score of 10 or
greater indicates a raw score in the top 10% of all possible
reference genome SNVs, and a score of 20 or greater indi-
cates a raw score in the top 1%, regardless of the details of
the annotation set, model parameters, etc.
Raw scores offer superior resolution across the en-
tire spectrum, and preserve relative differences between
scores that may otherwise be rounded away in the scaled
scores (only six significant digits are retained in the scaled
scores). For example, the bottom 90% (∼7.7 billion) of
all GRCh37/hg19 reference SNVs (∼8.6 billion) are com-
pressed into scaled CADD units of 0 to 10, while the next
9% (top 10% to top 1%, spanning ∼774 million SNVs)
occupy CADD-10 to CADD-20, etc. As a result, many
variants that have substantively different raw scores may
have very similar, or even the same, scaled scores; and
scaled scores accurately resolve differences between vari-
ants’ scores only at the extreme top end. Thus, when com-
paring distributions of scores between groups of variants
(e.g. variants seen in cases versus variants seen in con-
trols), raw scores should be used. However, when discov-
ering causal variants or fine-mapping variants within as-
sociated loci, scaled scores are advantageous as they allow
the user a direct interpretation in terms of the estimated
pathogenicity relative to all possible SNVs in the reference
genome.
It is tempting to declare a single universal cut-off value
for CADD scores, above which a variant is declared
‘pathogenic’ (or ‘functional’ or ‘deleterious’) as opposed to
‘benign’ (or ‘non-functional’ or ‘neutral’) across all datasets.
However, we believe that such an approach is flawed for at
least two reasons. First, a substantial loss of information
would result from binarizing continuous-valued CADD
scores. Second, the choice of cut-off would naturally depend
on a number of analysis-specific factors, such as the sever-
ity of the phenotype, whether the variant is dominant or re-
cessive, and the amount of time and resources available for
curation or experimental follow-up of variants. Therefore,
we recommend ranking all variants by CADD score, and
then further investigating the top-ranked variants to the ex-
tent that is meaningful within the given study design or al-
lowed by the available resources for follow-up assessment.
However, for an alternative view on this topic, we refer the
reader to recent methods that use CADD scores in conjunc-
tion with hard cutoffs; see GAVIN (23) and MSC (24). We
also note that for better or worse, the binary classification
of variants as pathogenic versus benign is still the standard
practice (and perhaps the expectation) in the medical genet-
ics field.
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THE IMPACT OF CADD SCORES IN HUMAN GENET-
ICS
The primary use of CADDhas been to score variants across
the reference genome to identify those that are most likely
to be deleterious and potentially pathogenic. Thus, its ma-
jor application is the prioritization of variants from among
thousands to millions of candidates. This includes variants
from clinical studies, like de novo, dominant and recessive
variants discovered in family-based sequencing (e.g. 23,25–
28), as well as variants identified in population-based stud-
ies (e.g. 29). Since its introduction in 2014, CADD has
become one of the most widely used tools to assess hu-
man genetic variation, and other tools and scores often
use CADD to benchmark their performance; according to
Google Scholar CADD has been cited 1984 times (as of 15
September 2018) with about 24 000 unique users of its web-
site over the last year.
Furthermore, CADD has also seen applications in evo-
lutionary studies, ranging from the interpretation of evolu-
tionary changes (30–32) to the theoretical investigation of
variant fitness effects in human populations (33).
The release of CADD has also spurred the development
of several other genome-wide predictors. For instance, the
feature set from CADD has been used to train Deep Neu-
ral Networks (e.g. DANN (34)), and CADD’s underlying
approach and training set definition methodology has been
adapted for othermodel organisms (35). A similar approach
based on ape-lineage-derived variants has been used to
score non-synonymous variants (36). CADD has also been
used to develop tools for complex variants, like scoring the
effect of larger structural variants (e.g. SVScore (37)). Some
recently developed predictors are ensemble learners, which
combine CADD and other scores (38–41). However, we are
not aware of any competing tool for variant-scoring that
consistently outperforms CADD in comprehensive testing
across diverse use cases in human genetics.
CADD UPDATES AND SUPPORT OF GRCh38
Since the initial release of CADD in 2014, we have pub-
lished four score updates. Besides, minor bug fixes and ad-
justments to the genomic features (Supplementary Table
S3), the main change between these releases was the choice
of the machine learning algorithm and software library. A
major challenge in training a CADDmodel is the size of the
fully annotated training dataset, which comprises hundreds
of gigabytes if stored naively. This is difficult to handle in
active working memory, and therefore needs to be kept in
a sparse matrix representation or handled using other com-
putational techniques. While CADD v1.0 used a linear sup-
port vector machine implemented in the LIBOCAS library
(42), latermodels usedL2-regularized logistic regression im-
plemented in GraphLab Create (43). For the latest release,
CADD v1.4, a logistic regression model was fit using a fully
open source pipeline based on SciPy (44) and scikit-learn
(45). All libraries permit model training in sparse matrix
format, with major benefits in terms of run time and mem-
ory requirements.
A performance comparison of our latest set of CADD
models to other commonly used scores is available in Figure
2.We validate CADD’s ability to separate variants reported
to be pathogenic in the NCBI/NIH ClinVar database (7)
from common variants (mean allele frequency> 0.05) in the
ExAC database (8), including a comparison matching mis-
sense variants in the same genes (see Supplementary Mate-
rials for more details). We also highlight that CADD score
performance extends beyond missense variants and across
different variant effect categories, such as those measured
by experimental assessments of transcriptional regulatory
influence.
CADD v1.0-v1.3 made use of the human genome build
GRCh37. In the latest release, v1.4, we also provide scores
for the human genome build GRCh38. Because new anno-
tations primarily supportGRCh38, and coordinate liftovers
are limited to regions well characterized in both genome
builds, the new model is based almost entirely on annota-
tions generated on GRCh38 (see Supplementary Materi-
als). We chose annotations that are identical or similar to
those used in the CADD GRCh37-v1.4 model. Although
training and parameter optimization were performed inde-
pendently on GRCh37 and GRCh38 models, for regions
well-represented in both genome builds, the fitted models
provided very similar variant scores (Figure 3). In total,
CADD v1.4 covers 2 937 639 113 bases on GRCh38 com-
pared to 2 858 658 094 bases on GRCh37. When compared
through coordinate liftover on a random sample of sites, the
two different releases show very similar score distributions
with Pearson correlation of 0.79 (Supplementary Figure S2,
GRCh37-v1.4 and v1.3 have a Pearson correlation of 0.89).
WEB ACCESS AND SCORE AVAILABILITY
CADD is available for SNVs as well as InDels shorter than
50 bp located on the 22 human autosomes and chromosome
X. We further provide scores for chromosome Y, although
not all annotations are available. Due to a lack of available
annotations, we currently do not support alternative haplo-
types and other contigs. In previous releases, CADD scored
variants located on the mitochondrial genome. However,
due to differences in inheritance, gene density, transcription
machinery and the availability of annotations, we have de-
cided to no longer support scoring of mitochondrial vari-
ants.
CADD scores, and the associated software, are freely
available for all non-commercial applications. They are
primarily distributed through our website (https://cadd.gs.
washington.edu), but there are a number of different ways
to obtain them (Figure 4). With the latest release, we have
considerably improved and extended the services provided.
As with all prior versions, users can perform scoring of
SNVs or short InDels online via upload of a VCF file or
can download pre-scored variant sets, including the scores
of ∼9 billion potential SNVs created from the human ref-
erence sequence. For users only interested in a small num-
ber of SNVs, the score lookup process can now be simpli-
fied and accelerated by either retrieving pre-scored SNVs
via tabix (46), or through a new interface that provides
scores and annotations for a single SNV, a genomic coor-
dinate, or ranges thereof. This score lookup also includes
further information about variants of interest by linking
to external resources like Ensembl (47), NCBI Genome
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Figure 2. Performance of CADD in comparison to other scores. Different scores are compared by area under the receiver operating characteristic (AU-
ROC) in terms of how well they separate known pathogenic variants (ClinVar pathogenic) from frequent exome variants (ExAC, mean allele frequency
>5%, assumed to be neutral): (A) All variants of the two sets, and (B) missense variants only, with matching genes between the two sets. PolyPhen2 and
PROVEAN, two dedicated protein missense variant scores, perform on par with CADD and Eigen, while all other scores have a lower AUROC. The
performance of CADD GRCh38-v1.4 is not significantly different from the other CADD releases. The results for more missense scores and non-coding
variants are shown in Supplementary Figure S1.
Figure 3. Comparison of CADD v1.3 and v1.4 in the UCSC Genome Browser: CADD GRCh38-v1.4 scores (light blue) in comparison to lifted scores
of the models of CADD v1.3 (pink) and v1.4 (gray) originally obtained for the GRCh37 genome build. Each browser track shows the maximum CADD
score of the three possible SNVs at each genomic position.
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Figure 4. Available CADD services. (A) The web server https://www.cadd.gs.washington.edu provides a rich resource for obtaining CADD scores and the
underlying annotations on which they are based, as well as scripts, documentation, etc. (B) There are several ways to obtain CADD scores. First, CADD
scores can be calculated for SNVs and short InDels using offline scripts or our website. Second, pre-scored SNVs and InDels can be obtained from indexed
files via the graphical website interface, API or through tabix.
Data Viewer (https://www.ncbi.nlm.nih.gov/genome/gdv/),
UCSC Genome Browser or gnomAD.
In order to enable external sources to refer directly to
CADD scores, we have enabled direct links to the scores of
SNVs, and we now provide an application programming in-
terface (API) to retrieve scores. At last, we also provide big-
Wig files of the maximum SNV score per genomic position
that can be visualized as browser tracks for utilities like the
UCSC genome browser (Figure 3) or Integrative Genomics
Viewer (IGV), and allow users to screen larger genomic ar-
eas quickly.
For users interested in scoring SNV and InDel vari-
ants on their own system, we provide software for of-
fline scoring, starting with CADD v1.1. Offline scoring
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takes a VCF file as input, and allows for retrieval of an-
notations from pre-scored variant sets, and annotation
and scoring of the remaining variants. It returns a gzip-
compressed tab-separated text file (tsv.gz) containing all
scored variants, with or without annotations. In the latest
release, we have simplified the installation process by in-
troducing dependency management through conda (https:
//conda.io), and providing an installation script that down-
loads all necessary annotations and, optionally, pre-scored
variants. The source code for offline CADD scoring is
available on GitHub (https://github.com/kircherlab/cadd-
scripts) and open to contribution by others.
In addition, our SNV scores are available through a num-
ber of third-party sources, such as dbNSFP (48), as a plug-
in for Ensembl VEP, ANNOVAR (49), SeattleSeq (50),
ExAC/gnomAD (8) and PopViz (51). We note that at the
time of this publication, these third-party sources do not
distinguish between CADD forGRCh38 andGRCh37, and
may well annotate lifted CADD v1.3 scores to GRCh38
variants.
FUTURE WORK
In general, integrative annotations like CADDbenefit enor-
mously from domain-specific scores such as PolyPhen2 and
SIFT, which boost performance in the coding regions of
the genome. In the future, we plan to add more domain-
specific scores and annotations to advance CADD scores in
regions of the genome that are not protein-coding. For ex-
ample, CADD currently does not include any information
about non-coding RNA species besides predicted miRNA
binding sites. Of special interest are regulatory variants in
promoters, enhancers and near splice sites, as a number of
other recent variant classifiers (26,52–55) have shown the
potential of predicting regulatory effects from sequence and
annotations describing the biological function. Specialized
scores derived from functionally testing large numbers of
variants via multiplex assays (56,57) may also be integrated
into CADD in the near future.
Further improvement ofCADDcould also come in terms
of amore complex, structuredmodel that combines features
via linear or non-linear interactions. Currently, CADD in-
cludes features obtained by taking the product of VEP-
predicted variant consequences with a number of anno-
tations, such as conservation and transcript position. In
the future, a more sophisticated and streamlined approach
could be applied in order to allow for non-linearity and in-
teractions within CADD. However, this must be performed
with care, as the risk of overfitting such complex models is
high.
DISCUSSION
In this manuscript, we presented an overview of recent up-
dates to CADD, as well as the services that we provide in
order to make those scores available and maximally use-
ful to the scientific community. In addition to better doc-
umentation and a fresh web layout, we substantially ex-
panded the options for how users can access scores by pro-
viding website and API lookups, genome browser tracks
and an easy-to-install offline scoring script.With the release
of CADD v1.4, we support direct (non-lifted) variant inter-
pretation on GRCh38 and show that the available annota-
tions provide a similar level of accuracy to those generated
for GRCh37.
A key strength of CADD is that the model is trained on
a very large training set that does not suffer from ascertain-
ment bias inherent to curated sets of pathogenic and benign
variants such as ClinVar (7) or HGMD (58). CADD shares
this strengthwith only a fewother scores, such as Eigen (59),
LINSIGHT (60) and CDTS (61). As a general statement,
we believe that CADD and tools like it that: (i) integrate
many correlated genomic annotations in a principled fash-
ion; (ii) rely on large training datasets to minimize the risk
of overfitting; and (iii) avoid curated sets of pathogenic and
benign variants during training, represent the best path for-
ward for predicting the relative pathogenicity or functional
importance of human genetic variants on a genome-wide
basis.
As genomic annotations grow in depth and breadth,
CADD and CADD-inspired variant scores will continue
to improve and provide utility across a wide range of an-
alytical scenarios. While this is particularly true for studies
of Mendelian disease, many complex-trait, comparative ge-
nomic, population genetic and functional genomic studies
are likely to also benefit from current and future versions of
CADD and related frameworks.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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